115955-48-1

Basic information

• Product Name: 3-(DIMETHYLAMINO)-1-(3-NITROPHENYL)-2-PROPEN-1-ONE
• Synonyms: 3-(DIMETHYLAMINO)-1-(3-NITROPHENYL)-2-PROPEN-1-ONE;(2E)-3-(Dimethylamino)-1-(3-nitrophenyl)prop-2-en-1-one
• CAS NO: 115955-48-1
• Molecular Formula: C₁₁H₁₂N₂O₃
• Molecular Weight: 220.22
• Mol File: 115955-48-1.mol

Chemical Properties

• Melting Point: 109-111 °C
• Boiling Point: 341.4±42.0 °C(Predicted)
• Appearance: /
• Density: 1.202±0.06 g/cm3(Predicted)
• Storage Temp.: 2-8°C
• PKA: 6.24±0.70(Predicted)
• CAS DataBase Reference: 3-(DIMETHYLAMINO)-1-(3-NITROPHENYL)-2-PROPEN-1-ONE(CAS DataBase Reference)
• NIST Chemistry Reference: 3-(DIMETHYLAMINO)-1-(3-NITROPHENYL)-2-PROPEN-1-ONE(115955-48-1)
• EPA Substance Registry System: 3-(DIMETHYLAMINO)-1-(3-NITROPHENYL)-2-PROPEN-1-ONE(115955-48-1)

Safety Data

• HazardClass: IRRITANT
• Hazardous Substances Data: 115955-48-1(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
3-(DIMETHYLAMINO)-1-(3-NITROPHENYL)-2-PROPEN-1-ONE is used as a pharmaceutical intermediate for the synthesis of various drugs. Its unique chemical structure allows it to be a key component in the development of new medications.
Used in Chemical Industry:
3-(DIMETHYLAMINO)-1-(3-NITROPHENYL)-2-PROPEN-1-ONE is used as a reactant in the production of dyes and pigments. Its color properties make it suitable for creating a wide range of hues in various applications.
Used in Research and Development:
3-(DIMETHYLAMINO)-1-(3-NITROPHENYL)-2-PROPEN-1-ONE is used as a fluorescent probe or staining reagent in biological and biochemical studies. Its ability to emit fluorescence under certain conditions makes it a valuable tool for researchers in various scientific fields.
Used in Organic Synthesis:
3-(DIMETHYLAMINO)-1-(3-NITROPHENYL)-2-PROPEN-1-ONE is used as a reactant in organic synthesis for the creation of new chemical compounds. Its versatile structure allows it to be a building block for a variety of organic molecules.

Upstream product

• 4637-24-5 N,N-dimethyl-formamide dimethyl acetal 
• 121-89-1 3-Nitroacetophenone 

Downstream Products

• 59843-77-5 5-(3-nitrophenyl)-1H-pyrazole 
• 1025833-51-5 tert-butyl 5-(3-nitrophenyl)-1H-pyrazole-1-carboxylate 
• 850786-63-9 [7-(3-nitrophenyl)pyrazolo[1,5-a]pyrimidin-3-yl]-2-thienyl-methanone 
• 765292-65-7 ethyl 7-(3-nitrophenyl)pyrazolo[1,5-a]pyrimidine-3-carboxylate 
• 4264-04-4 3-(3-nitro-phenyl)-isoxazole 
• 950739-42-1 7-(3-nitrophenyl)-2-pyridin-4-ylpyrazolo[1,5-a]pyrimidine 

Relevant articles and documents

Assessment of new triplet forming artificial nucleobases as RNA ligands directed towards HCV IRES IIId loop

We report the synthesis of two new artificial nucleobase scaffolds, 1 and 2, featuring adequate hydrogen bonding donors and acceptors for the molecular recognition of U:A and C:G base pairs, respectively. The tethering of these structures to various amino acids and the assessment of these artificial nucleobase-amino acid conjugates as RNA ligands against a model of HCV IRES IIId domain are also reported. Compound 1e displayed the highest affinity (Kd twice lower than neomycin – control). Moreover, it appears that this interaction is enthalpically and entropically favored.

Selective Synthesis of Site-Differentiated Fe4S4 and Fe6S6 Clusters

Obtaining rational control over the structure and nuclearity of metalloclusters is an ongoing challenge in synthetic Fe-S cluster chemistry. We report a new family of tridentate imidazolin-2-imine ligands L(NImR)3 that can bind [Fe4S4]2+ or [Fe6S6]3+ clusters, depending on the steric profile of the ligand and the reaction stoichiometry. A high-yielding synthetic route to L(NImR)3 ligands (where R is the imidazolyl N substituents) from trianiline and 2-chloroimidazolium precursors is described. For L(NImMe)3 (tris(1,3,5-(3-(N,N-dimethyl-4,5-diphenylimidazolin-2-imino)phenylmethyl))benzene), metalation with 1 equiv of [Ph4P]2[Fe4S4Cl4] and 3 equiv of NaBPh4 furnishes a mixture of products, but adjusting the stoichiometry to 1.5 equiv of [Ph4P]2[Fe4S4Cl4] provides (L(NImMe)3)Fe6S6Cl6 in high yield. Formation of an [Fe6S6]3+ cluster using L(NImTol)3 (tris(1,3,5-(3-(N,N-bis(4-methylphenyl)-4,5-diphenylimidazolin-2-imino)phenylmethyl))benzene) is not observed; instead, the [Fe4S4]2+ cluster [(L(NImTol)3)(Fe4S4Cl)][BPh4] is cleanly generated when 1 equiv of [Ph4P]2[Fe4S4Cl4] is employed. The selectivity for cluster nuclearity is rationalized by the orientation of the imidazolyl rings whereby long N-imidazolyl substituents preclude formation of [Fe6S6]3+ clusters but not [Fe4S4]2+ clusters. Thus, the structure and nuclearity of L(NImR)3-bound Fe-S clusters may be selectively controlled through rational modification the ligand's substituents.

Design, synthesis, in silico, and in vitro evaluation of 3-phenylpyrazole acetamide derivatives as antimycobacterial agents

Mycobacterium tuberculosis (Mtb) is one of the most dangerous pathogens affecting immunocompetent and immunocompromised patients worldwide. Novel molecules, which are efficient and can reduce the duration of therapy against drug-resistant strains, are an

COMPOUND OF 5-HYDROXYL-1,7-NAPHTHYRIDINE SUBSTITUTED BY ARYL OR HETEROARYL, PREPARATION METHOD THEREOF AND PHARMACEUTICAL USE THEREOF

Disclosed are a compound of the following formula (I) or a pharmaceutically acceptable salt thereof, a preparation method thereof, pharmaceutical compositions and uses thereof in the preparation of a medicine for inhibiting HIF prolyl hydroxylase or a medicine for promoting the generation of endogenous EPO, wherein in the formula (I), R1 and R2 are each independently hydrogen; R3 is hydrogen or C1-3 alkyl; and Ar is an aromatic ring or an heteroaromatic ring selected from a naphthalene ring, a pyridine ring, a thiophene ring, a furan ring and a substituted benzene ring.

Identification of pyrazolo[1,5-a]pyrimidine-3-carboxylates as B-Raf kinase inhibitors

B-Raf kinase plays a critical role in the Raf-MEK-ERK signaling pathway and inhibitors of B-Raf could be used in the treatment of melanomas, colorectal cancer, and other Ras related human cancers. We have identified novel small molecule pyrazolo[1,5-a]pyr

Hit to lead optimization of pyrazolo[1,5-a]pyrimidines as B-Raf kinase inhibitors

Our continued effort towards optimization of the pyrazolo[1,5-a]pyrimidine scaffold as B-Raf kinase inhibitors is described. Structure guided design was utilized to introduce kinase hinge region interacting groups in the 2-position of the scaffold. This s

3-AZABICYCLO [3.1.0] HEXANE DERIVATIVES AS VANILLOID RECEPTOR LIGANDS

The present invention relates to 3-azabicyclo[3.1.0]hexane derivatives, which are useful as vanilloid receptor (VR) ligands, methods of treating diseases, conditions and/or disorders modulated by vanilloid receptors with them, and processes for preparing them.

Dihydropyrazolo[1,5-A]pyrimidine and dihydroimidazo[1,5-A]pyrimidine derivatives and methods of use thereof

The present invention relates to dihydropyrazolo[1,5-a]pyrimidine and dihydroimidazo[1,5-a]pyrimidine derivatives, compositions comprising an effective amount of a dihydropyrazolo[1,5-a]pyrimidine or a dihydroimidazo[1,5-a]pyrimidine derivative and method

Pyrazolo[1,5-A]pyrimidine derivatives and methods of use thereof

The present invention relates to pyrazolo[1,5-a]pyrimidine derivatives, compositions comprising an effective amount of a pyrazolo[1,5-a]pyrimidine derivative and methods for treating or preventing cancer, comprising administering to a subject in need thereof an effective amount of a pyrazolo[1,5-a]pyrimidine derivative.

Method of using substituted pyrazolo [1,5-a] pyrimidines

This invention relates to novel methods of use of certain pyrazolo[1,5-a]pyrimidine compounds and the therapeutically acceptable salts thereof. This invention also relates to novel methods of using these compounds as anti-proliferative agents in mammals, including humans.